Thanes Vanig, MD
Infectious Disease · Phoenix, AZNPI 1215925441
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $170,214 of the $258,384 with a category attached, or 65.9%. Gilead accounts for 66.3% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $101,682 and has fallen 95.3% since, to $4,740 in 2025. Among infectious disease clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 604 payments — averaging $427.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$171K
- Janssen Products, LP$44K
- Viiv Healthcare Company$27K
- Merck$13K
- Janssen Scientific Affairs, LLC$839
- Johnson & Johnson$695
- plus $2K from 18 others
Across 87 payments — averaging $2448.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$109K
- Viiv Healthcare Company$104K
What the payments were for
- Consulting fees$50,02519%
- Speaking & faculty fees$170,21466%
- Travel & lodging$26,21410%
- Food & beverage$11,8235%
- Education$1080%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 299 | $171,307 |
| Janssen Products, LP | 45 | $44,473 |
| Viiv Healthcare Company | 76 | $26,891 |
| Merck | 46 | $12,519 |
| Janssen Scientific Affairs, LLC | 2 | $839 |
| Johnson & Johnson(2 entities) | 48 | $695 |
| Pfizer | 36 | $537 |
| AbbVie(2 entities) | 12 | $244 |
| Theratechnologies Inc. | 10 | $189 |
| Hologic Sales And Service, LLC | 2 | $175 |
| EMD Serono, Inc. | 10 | $171 |
| GSK | 3 | $123 |
| Napo Pharmaceuticals Inc | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $24 |
| AstraZeneca | 2 | $23 |
| Endo Pharmaceuticals Inc. | 1 | $21 |
| Nalu Medical, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $18 |
| Novo Nordisk | 1 | $15 |
| Mylan Institutional Inc. | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Antares Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$258,384 in reported general payments places this provider in the 95th percentile of 146 infectious disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 313 | $1,429,685 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 91 | $478,800 |
| DovatoDolutegravir Sodium/Lamivudine | 127 | $404,528 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 90 | $389,209 |
| DescovyEmtricitabine/Tenofov Alafenam | 146 | $355,985 |
| PrezcobixDarunavir/Cobicistat | 101 | $301,847 |
| TivicayDolutegravir Sodium | 77 | $199,825 |
| IsentressRaltegravir Potassium | 70 | $164,133 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 34 | $122,063 |
| JulucaDolutegravir/Rilpivirine | 26 | $95,336 |
| Etravirine | 41 | $43,038 |
| DelstrigoDoravirine/Lamivu/Tenofov Diso | 13 | $38,512 |
| AptivusTipranavir | 12 | $26,670 |
| JardianceEmpagliflozin | 35 | $25,724 |
| Darunavir | 23 | $24,190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $171,307 | $2,174,879549 claims |
| Viiv Healthcare CompanyDovato, Tivicay, Juluca | $26,891 | $699,689230 claims |
| Janssen Products, LPSymtuza | $44,473 | $478,80091 claims |
| Johnson & JohnsonPrezcobix | $695 | $301,847101 claims |
| MerckIsentress, Delstrigo | $12,519 | $202,64583 claims |
| Boehringer IngelheimAptivus, Jardiance | $18 | $52,39447 claims |
| PfizerEliquis | $537 | $16,01914 claims |
| GSKTrelegy Ellipta | $123 | $11,52513 claims |
| Antares Pharma, Inc.Xyosted | $11 | $9,86716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 146 infectious disease providers in Arizona.
Other infectious disease in Phoenix
- Vipul GanatraPhoenix$151K
- Ana MoranPhoenix$35K
- Robert OrensteinPhoenix$26K
- Adriana GaidiciPhoenix$20K
- Dwight ClarkePhoenix$18K
- Ndidiamaka ObiesiePhoenix$12K
- Ngozi OsonduPhoenix$5K
- Mirella MircescuPhoenix$4K
- Rebekah SensenigPhoenix$3K
- Edwin YuPhoenix$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.